BNTC
Benitec Biopharma Inc.Company Information
- Company Name
- Benitec Biopharma Inc.
- CIK
- CIK0001808898
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BNTC: Nasdaq
- Fiscal Year End
- June 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BNTC
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-29
- Last sale
- —
- Shares purchased (TTM)
- 2,491,749
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 33,191,835
- Shares outstanding
- 46,558,162
- Ownership
- 71.29%
Earnings Market Reaction
- Filing date
- 2026-09-14
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 180 | 185 | 189 | 94 | 98 | 104 | 78 | 68 | 51 | - | 20 | 26 | ||||||
| Due From Banks | - | - | - | - | - | - | - | - | 51 | 14 | - | - | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts And Other Receivables Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | ||||||
| Assets Current | 182 | 186 | 190 | 95 | 99 | 104 | 79 | 68 | 52 | 14 | 21 | 26 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deposit Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 183 | 187 | 191 | 96 | 100 | 105 | 79 | 69 | 52 | 15 | 21 | 27 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Other Accrued Liabilities Current | 4 | 2 | 2 | 1 | 1 | 6 | 2 | 4 | 4 | 3 | 5 | 4 | ||||||
| Employee Related Liabilities Current | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 5 | 3 | 3 | 2 | 2 | 7 | 3 | 5 | 5 | 3 | 6 | 5 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 1 | 0 | 0 | 1 | - | - | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 6 | 4 | 3 | 2 | 2 | 8 | 3 | 5 | 5 | 3 | 6 | 5 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 452 | 445 | 437 | 331 | 326 | 310 | 279 | 260 | 238 | 197 | 197 | 197 | ||||||
| Retained Earnings Accumulated Deficit | -274 | -261 | -249 | -237 | -228 | -212 | -203 | -195 | -190 | -185 | -181 | -174 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Stockholders Equity | 177 | 183 | 187 | 94 | 97 | 98 | 76 | 64 | 47 | 12 | 15 | 22 | ||||||
| Liabilities And Stockholders Equity | 183 | 187 | 191 | 96 | 100 | 105 | 79 | 69 | 52 | 15 | 21 | 27 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 160 | 160 | 160 | 160 | 160 | 160 | 160 | 160 | 160 | 160 | 160 | 160 | ||||||
| Common Stock Shares Issued | 34 | 34 | 34 | 26 | 26 | 26 | 23 | 18 | 10 | 3 | 3 | 3 | ||||||
| Shares Outstanding | 34 | 34 | 34 | 26 | 26 | 26 | 23 | 18 | 10 | 3 | 3 | 3 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - | - | - | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | 5 | - | - | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBenitec Biopharma Inc. (BNTC) — SEC Financial Statements & Analysis
Benitec Biopharma Inc. (BNTC) is a pharmaceutical preparations company, incorporated in DE. Benitec Biopharma Inc. trades on Nasdaq as: BNTC. Benitec Biopharma Inc. (BNTC)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-14. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Benitec Biopharma Inc. carries a market cap of $622.95M, a P/E ratio of -13.68x, a P/B ratio of 3.52x, a P/S ratio of 13711.42x, an enterprise value of $442.86M, and an EV/EBITDA multiple of -8.66x. On profitability, it posts an operating margin of -307028.57%, a net margin of -309885.71%, a Return on Equity (ROE) of -33.21%, a Return on Assets (ROA) of -32.28%, and a Return on Invested Capital (ROIC) of -100.04%. Per share, it reports EPS of $-0.98, diluted EPS of $-0.98, free cash flow per share of $-0.36, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 20.12% year-over-year, and EPS growth of -6.58% year-over-year. On the balance sheet, it maintains a current ratio of 34.00x, a quick ratio of 33.70x, working capital of $176.34M, a debt-to-equity ratio of 0.03x, a debt ratio of 0.03, an interest coverage ratio of -9.19x, free cash flow of $-16.62M (TTM), and net debt of $-180.09M. Figures sourced from SEC EDGAR.
- Market Cap
- $622.95M
- P/E TTM
- -13.68x
- EPS TTM
- $-0.98
- P/B TTM
- 3.52x
- ROE TTM
- -33.21%
- ROA TTM
- -32.28%
- Debt To Equity
- 0.03x
- Free Cash Flow TTM
- $-16.62M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Benitec Biopharma Inc. in?
Benitec Biopharma Inc. (BNTC) operates in the Pharmaceutical Preparations industry.
What exchange does BNTC trade on?
Benitec Biopharma Inc. (BNTC) trades on the Nasdaq.
Where is Benitec Biopharma Inc. incorporated?
Benitec Biopharma Inc. is incorporated in DE.
When was Benitec Biopharma Inc. (BNTC)'s most recent SEC filing?
Benitec Biopharma Inc. (BNTC)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-14.
What is BNTC's market cap?
Benitec Biopharma Inc. (BNTC) has a market capitalization of $622.95M as of 2026-06-30.
What is BNTC's EPS (earnings per share)?
Benitec Biopharma Inc. (BNTC)'s trailing twelve month EPS is $-0.98 as of 2026-06-30.
What is BNTC's ROE (return on equity)?
Benitec Biopharma Inc. (BNTC)'s trailing twelve month Return on Equity (ROE) is -33.21% as of 2026-06-30.
What is BNTC's ROA (return on assets)?
Benitec Biopharma Inc. (BNTC)'s trailing twelve month Return on Assets (ROA) is -32.28% as of 2026-06-30.
What is BNTC's ROIC (return on invested capital)?
Benitec Biopharma Inc. (BNTC)'s trailing twelve month Return on Invested Capital (ROIC) is -100.04% as of 2024-06-30.
What is BNTC's EV/EBITDA?
Benitec Biopharma Inc. (BNTC)'s trailing twelve month EV/EBITDA is -8.66x as of 2026-06-30.